15 studies found for:    "Morphea"
Show Display Options
Rank Status Study
1 Terminated Molecular Effects of Topical Calcipotriene on Morphea
Conditions: Morphea;   Localized Scleroderma
Intervention: Drug: topical calcipotriene 0.005% ointment
2 Completed Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea.
Condition: Symmetric Limited Morphea.
Interventions: Other: Medium Dose UVA-1;   Other: High Dose UVA-1
3 Withdrawn Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study
Condition: Morphea
Intervention: Drug: imiquimod 5% cream (Aldara)
4 Recruiting Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository
Conditions: Scleroderma, Localized;   Morphea;   Frontal Linear Scleroderma en Coup de Sabre;   Scleroderma, Circumscribed;   Scleroderma, Linear
Intervention: Other: Morphea
5 Recruiting Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for Morphea
Conditions: Scleroderma, Localized;   Morphea;   Scleroderma, Circumscribed
Interventions: Procedure: UVA-1 Phototherapy;   Procedure: Placebo
6 Recruiting Genetic Variants in Linear Localized Scleroderma
Condition: Morphea
Intervention: Other: skin biopsy
7 Recruiting Fractional Carbon Dioxide Laser Versus UVA 1 in Treatment of Localized Scleroderma
Condition: Localized Scleroderma
Interventions: Device: Fractional carbon dioxide laser;   Device: Ultraviolet A1 phototherapy (UVA1)
8 Completed Imiquimod in Children With Plaque Morphea
Condition: Scleroderma, Localized
Intervention: Drug: Imiquimod 5% cream
9 Recruiting Safety, Tolerability and Pharmacokinetic Study of MRG-201 in Healthy Volunteers and Patients With Cutaneous Scleroderma
Conditions: Limited Scleroderma;   Localized Scleroderma;   Diffuse Scleroderma
Interventions: Drug: MRG-201;   Drug: Placebo
10 Not yet recruiting Comparative Effectiveness Trial in the Treatment of Pediatric Plaque Morphea
Condition: Scleroderma
Interventions: Drug: Clobetasol;   Drug: Calcipotriene;   Drug: Tacrolimus
11 Completed The CARRA Registry
Conditions: Juvenile Idiopathic Arthritis;   Systemic Lupus Erythematosus;   Mixed Connective Tissue Disease;   Juvenile Ankylosing Spondylitis;   Juvenile Dermatomyositis;   Localized Scleroderma;   Systemic Sclerosis;   Vasculitis;   Sarcoid;   Fibromyalgia, Primary;   Auto-inflammatory Disease;   Idiopathic Uveitis Idiopathic
Intervention:
12 Unknown  A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy
Condition: Debilitating Fibrosing Skin Disorders (Localised Scleroderma, Eosinophilic Fasciitis)
Intervention: Drug: Rituximab
13 Recruiting Microvascular and Fibrosis Imaging Study
Conditions: Autoimmune Diseases;   Sickle Cell Disease;   Chronic Graft Versus Host Disease
Interventions: Other: Acoustic Radiation Force Impulse (ARFI);   Other: Laser Doppler Flowmetry (LDF);   Other: Laser Doppler Perfusion Imaging (LDI);   Other: Optical Coherence Tomography (OCT);   Other: Orthogonal Polarization Spectral Imaging (OPSI);   Other: Nail fold video capillaroscopy (NVC)
14 Completed UVA1 Light for Treatment of Scleroderma and Similar Conditions
Conditions: Scleroderma;   Keloids;   Other Fibrosing Conditions
Intervention: Device: German manufactured UVA1 light emitting device
15 Terminated UVA1 Light for Scleroderma and Similar Conditions
Conditions: Keloid;   Scleroderma;   Scars;   Granuloma Annulare;   Acne Keloidalis Nuchae
Intervention: Device: German manufactured UVA1 emitting light system

Indicates status has not been verified in more than two years